Psychedelic medicine is hot right now—or regulatory agencies seem to be warming up to the idea, at least. Over the last few years, the FDA has begun to approve (and even fast-track) clinical trials examining the impact of substances like ketamine, psilocybin, and MDMA on mental health issues like post-traumatic stress disorder and major depressive disorder. In addition to contributing to the growing ...
Help us caption and translate this video on Amara.org: http://www.amara.org/en/videos/ypBoaytF37qb/info/
Results of the Long-Term Outcomes Study of Ibogaine Treatment in Mexico
Thomas Kingsley Brown, PhD
This presentation is an overview of the MAPS-funded study of long-term outcomes for ibogaine-assisted treatment of opiate dependence for patients at two clinics in Baja California, Mexico. Beginning in September of 2010, the study enrolled thirty US residents seeking ibogaine treatment for opiate dependence at the ...
Help us caption and translate this video on Amara.org: http://www.amara.org/en/videos/w5HzSJBjBSdf/info/
Notes on Progress in the New Zealand Ibogaine Study
Geoff Noller, PhD
This presentation reports on the first year of progress in the New Zealand observational study of ibogaine treatment outcomes for opioid-dependent persons. Current participants’ data are reviewed and the implications of New Zealand’s ibogaine legislation for research and treatment are discussed.